AI-guided treatment for high-grade ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial uses artificial intelligence to guide personalized treatment for people with a specific type of ovarian cancer (high-grade serous carcinoma). It aims to improve outcomes by analyzing your tumor tissue and medical history.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with high-grade serous ovarian cancer through surgery and biopsy.
- Your tumor tissue from surgery is stored in a paraffin block and is still in good condition.
- Your medical team has your complete medical records and follow-up data.
- You have not received chemotherapy or other drugs before your surgery.
- You do not have any other type of cancer besides high-grade serous ovarian cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized cancer therapy designed just for you and your tumor. It is for people with newly diagnosed advanced ovarian cancer who can wait a short time before starting treatment and plan to have surgery after 2 cycles of chemotherapy.
This study is for people with a specific type of ovarian cancer (high-grade serous) who have not yet had surgery. It looks at how the cancer may resist standard chemotherapy and aims to find ways to overcome that resistance.
This trial uses a special imaging technique to study high-grade serous ovarian cancer. It aims to better understand the tumor to improve treatment. If you have advanced ovarian cancer and are scheduled for surgery, you may be eligible.
This study looks at results from surgery to remove as much advanced ovarian cancer as possible after chemotherapy. Participating hospitals are in Italy and Canada.
This study is testing an AI system that uses your ultrasound or MRI images and blood test results to help doctors better diagnose ovarian tumors before surgery. It may lead to more accurate treatment planning.
This study looks at a protein called DHODH in a type of ovarian cancer. It compares two treatment approaches to see if the protein can help predict how well the cancer responds to therapy.
Hear when a new High-grade Serous Ovarian Carcinoma (HGSOC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.